131-iodine tositumomab for non-Hodgkin's lymphoma - horizon scanning review

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To summarise the available evidence on 131-Iodine tositumomab for non-Hodgkin's lymphoma (NHL).

Authors' conclusions
- Clinical impact: Iodine-131 tositumomab is entering a market with many other treatment options. Trial results suggest a beneficial effect on response and median time to relapse, although full results from trials are still awaited. An estimated 300 to 550 patients may be eligible for therapy with iodine-131 tositumomab. - Service impact: There is unlikely to be a significant service impact associated with the introduction of iodine-131 tositumomab, however an inpatient stay is required because of the possibility of radiation exposure to other people. The radiolabelling process and regulations will be familiar to nuclear medicine departments. - Additional factors: Because of its prolonged nature any drug with the potential to lengthen survival in NHL will be welcomed by doctors, patients and carers. - Financial and overall NHS impact: During the course of NHL patients are given many different regimes and iodine-131 tositumomab will be an additional cost, but in some cases it may replace or postpone other treatment options. This needs to be clarified in cost-effectiveness data.

Timeliness warning
Available on request from NHSC.

Final publication URL
http://www.hsric.nihr.ac.uk/search

Indexing Status
Subject indexing assigned by CRD

MeSH
Antibodies, Monoclonal /therapeutic use; Antineoplastic Agents /therapeutic use; Lymphoma, Non-Hodgkin /drug therapy

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
Department of Public Health&Epidemiology The University of Birmingham Edgbaston, Birmingham B15 2TT United Kingdom Tel: +44 121 414 7831; Fax: +44 121 414 2269 Email: c.packer@bham.ac.uk
AccessionNumber
32002000529

Date bibliographic record published
01/07/2002

Date abstract record published
01/07/2002